A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, cilt.13, sa.2, ss.156-160, 2008 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 13 Sayı: 2
- Basım Tarihi: 2008
- Doi Numarası: 10.1007/s10147-007-0740-4
- Dergi Adı: INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.156-160
- İstanbul Üniversitesi Adresli: Evet
Özet
Background. Both gemcitabine and pegylated liposomal doxorubicin (PLD) are antineoplastic drugs with clinical activity in patients with platinum-resistant ovarian cancer. The present study was designed to assess the efficacy and safety of biweekly scheduled gemcitabine and PLD combination therapy in such patients.